Kai Y - Search Results

1

Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.

Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, Takeshima Y. Fujii Y, et al. Among authors: kai y. Oncol Rep. 2022 Feb;47(2):27. doi: 10.3892/or.2021.8238. Epub 2021 Dec 3. Oncol Rep. 2022. PMID: 34859258 Free PMC article.

2

MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.

Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, Takeshima Y. Mawas AS, et al. Among authors: kai y. Sci Rep. 2018 Jan 9;8(1):134. doi: 10.1038/s41598-017-18545-x. Sci Rep. 2018. PMID: 29317712 Free PMC article.

3

Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.

Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, Takeshima Y. Amatya VJ, et al. Among authors: kai y. Mod Pathol. 2018 May;31(5):809-815. doi: 10.1038/modpathol.2017.190. Epub 2018 Jan 12. Mod Pathol. 2018. PMID: 29327712 Free article.

4

Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.

Ito M, Miyata Y, Kushitani K, Yoshiya T, Kai Y, Tsutani Y, Mimura T, Konishi K, Takeshima Y, Okada M. Ito M, et al. Among authors: kai y. Thorac Cancer. 2018 Dec;9(12):1594-1602. doi: 10.1111/1759-7714.12866. Epub 2018 Oct 8. Thorac Cancer. 2018. PMID: 30298562 Free PMC article.

5

Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.

Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y. Kai Y, et al. Histopathology. 2019 Mar;74(4):545-554. doi: 10.1111/his.13775. Epub 2019 Jan 15. Histopathology. 2019. PMID: 30329165

6

miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma.

Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Takeshima Y. Suzuki R, et al. Among authors: kai y. Front Oncol. 2018 Oct 22;8:446. doi: 10.3389/fonc.2018.00446. eCollection 2018. Front Oncol. 2018. PMID: 30406026 Free PMC article.

7

Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.

Handa Y, Tsutani Y, Shiroma N, Kai Y, Mimae T, Miyata Y, Takeshima Y, Arihiro K, Okada M. Handa Y, et al. Among authors: kai y. Clin Lung Cancer. 2020 Jul;21(4):e302-e314. doi: 10.1016/j.cllc.2020.01.013. Epub 2020 Jan 27. Clin Lung Cancer. 2020. PMID: 32102750

8

Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin.

Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y. Suzuki R, et al. Among authors: kai y. Oncol Lett. 2020 Jun;19(6):4161-4168. doi: 10.3892/ol.2020.11504. Epub 2020 Apr 1. Oncol Lett. 2020. PMID: 32382354 Free PMC article.

9

SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.

Kambara T, Amatya VJ, Kushitani K, Suzuki R, Fujii Y, Kai Y, Miyata Y, Okada M, Takeshima Y. Kambara T, et al. Among authors: kai y. Am J Surg Pathol. 2020 Sep;44(9):1259-1265. doi: 10.1097/PAS.0000000000001507. Am J Surg Pathol. 2020. PMID: 32496433

10

Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces.

Kagimoto A, Tsutani Y, Kushitani K, Kai Y, Kambara T, Miyata Y, Takeshima Y, Okada M. Kagimoto A, et al. Among authors: kai y. Ann Thorac Surg. 2021 Sep;112(3):935-943. doi: 10.1016/j.athoracsur.2020.09.020. Epub 2020 Nov 2. Ann Thorac Surg. 2021. PMID: 33144104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

872 results

Search Page

Filters